… in Q1 2022 Sepofarsen is a potential first-in-class RNAtherapy for the treatment of LCA10, a rare inherited retinal … to changing lives through the creation of transformative RNA therapies for genetic eye diseases today announced that …
… supports ProQR’s strategic focus on the Axiomer® RNA editing technology platform and continued advancement of … company dedicated to changing lives through transformative RNA therapies, and Laboratoires Théa, the leading independent … Sepofarsen Sepofarsen (QR-110) is an investigational RNAtherapy designed to restore vision in Leber congenital …
… expected H1 2022 Sepofarsen is a potential first-in-class RNAtherapy for the treatment of LCA10, a rare inherited retinal … to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today …
In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial pipeline targets expected in late 2022/early 2023
Additi
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … 1/2 clinical trial of QR-421a, an investigational RNAtherapy. The Stellar trial is a randomized, single ascending …
ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
… at the upcoming Seventh Annual Retinal Cell and Gene Therapy Innovation Summit and the ARVO 2022 Annual Meeting … to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today provided an update on its sepofarsen …
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today reported its financial and operating … were presented at the Seventh Annual Retinal Cell and Gene Therapy Innovation Summit, April 29, 2022, and the …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …